Theravance Reports Positive Phase 1 Data on TD-1473, a JAK Inhibitor for IBD

Theravance Reports Positive Phase 1 Data on TD-1473, a JAK Inhibitor for IBD
Theravance Biopharma, Inc., recently reported positive data from its Phase 1 clinical trial assessing TD-1473, a new and oral pan-Janus kinase (JAK) inhibitor designed to enter the gastrointestinal tract and target inflammation without significant systemic exposure. Proinflammatory cytokines play an important role in inflammatory bowel disease (IBD), many of which signal via the JAK/signal transducer and activator of transcription

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *